Oditrasertib, which blocks the inflammatory RIPK1 protein, earlier this year also failed a Phase II trial in amyotrophic lateral sclerosis, forcing the company to discontinue its development a few months later.

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditras | Sanofi has stopped a phase 2 trial of the Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after failing to meet its primary and secondary endpoints,

Denali Therapeutics said on Thursday its partner Sanofi has discontinued a mid-stage study testing their experimental drug to treat multiple sclerosis as it failed to meet the main and secondary study goals.

Sanofi (NASDAQ:SNY) has failed in another mid-stage trial for DNL788, an experimental therapy developed with Denali Therapeutics (NASDAQ:DNLI) for neurological conditions such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis.

Six years ago, Sanofi gave $125 million and promised over $1 billion in milestone payments to buzzy neuroscience startup Denali Therapeutics to go after a promising new target called RIPK1. That partnership has not gone well.